Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination.
Adaptive immunity
Cellular immune response
Immunology
Infectious disease
MHC class 2
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
03 02 2020
03 02 2020
Historique:
received:
18
04
2019
accepted:
31
10
2019
pubmed:
8
11
2019
medline:
17
9
2020
entrez:
8
11
2019
Statut:
ppublish
Résumé
BACKGROUNDChronic hepatitis C virus (HCV) infection is characterized by a severe impairment of HCV-specific CD4+ T cell help that is driven by chronic antigen stimulation. We aimed to study the fate of HCV-specific CD4+ T cells after virus elimination.METHODSHCV-specific CD4+ T cell responses were longitudinally analyzed using MHC class II tetramer technology, multicolor flow cytometry, and RNA sequencing in a cohort of patients chronically infected with HCV undergoing therapy with direct-acting antivirals. In addition, HCV-specific neutralizing antibodies and CXCL13 levels were analyzed.RESULTSWe observed that the frequency of HCV-specific CD4+ T cells increased within 2 weeks after initiating direct-acting antiviral therapy. Multicolor flow cytometry revealed a downregulation of exhaustion and activation markers and an upregulation of memory-associated markers. Although cells with a Th1 phenotype were the predominant subset at baseline, cells with phenotypic and transcriptional characteristics of follicular T helper cells increasingly shaped the circulating HCV-specific CD4+ T cell repertoire, suggesting antigen-independent survival of this subset. These changes were accompanied by a decline of HCV-specific neutralizing antibodies and the germinal center activity.CONCLUSIONWe identified a population of HCV-specific CD4+ T cells with a follicular T helper cell signature that is maintained after therapy-induced elimination of persistent infection and may constitute an important target population for vaccination efforts to prevent reinfection and immunotherapeutic approaches for persistent viral infections.FUNDINGDeutsche Forschungsgemeinschaft (DFG, German Research Foundation), the National Institute of Allergy and Infectious Diseases (NIAID), the European Union, the Berta-Ottenstein-Programme for Advanced Clinician Scientists, and the ANRS.
Identifiants
pubmed: 31697649
pii: 129642
doi: 10.1172/JCI129642
pmc: PMC6994124
doi:
pii:
Substances chimiques
Antiviral Agents
0
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
998-1009Subventions
Organisme : European Research Council
ID : 671231
Pays : International
Organisme : NIAID NIH HHS
ID : U19 AI123862
Pays : United States
Références
Immunity. 2011 Jan 28;34(1):108-21
pubmed: 21215658
Sci Rep. 2016 May 27;6:26494
pubmed: 27231124
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Exp Med. 2019 Mar 4;216(3):621-637
pubmed: 30723095
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Virus Res. 2018 Mar 15;248:53-62
pubmed: 29477639
Nat Commun. 2018 Jun 11;9(1):2275
pubmed: 29891939
J Hepatol. 2014 Sep;61(3):538-43
pubmed: 24905492
J Infect Dis. 2016 Dec 15;214(12):1965-1974
pubmed: 27683821
Immunity. 2013 Apr 18;38(4):805-17
pubmed: 23583644
Clin Infect Dis. 2019 May 2;68(10):1623-1630
pubmed: 30204855
J Leukoc Biol. 2003 Sep;74(3):360-9
pubmed: 12949239
Front Immunol. 2018 Jun 28;9:1480
pubmed: 30002657
Gastroenterology. 2017 Nov;153(5):1392-1403.e2
pubmed: 28780074
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Immunity. 2011 Sep 23;35(3):400-12
pubmed: 21943489
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Commun. 2017 May 03;8:15050
pubmed: 28466857
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
J Hepatol. 2018 Nov;69(5):1007-1014
pubmed: 30142429
J Hepatol. 2015 Feb;62(2):303-10
pubmed: 25281860
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Immunity. 2007 Aug;27(2):203-13
pubmed: 17707129
Sci Immunol. 2017 Feb;2(8):
pubmed: 28620653
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
pubmed: 17392433
Hepatology. 2008 Jun;47(6):1824-36
pubmed: 18454507
Sci Transl Med. 2013 Mar 13;5(176):176ra32
pubmed: 23486778
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9777-82
pubmed: 20457902
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
J Clin Invest. 2014 Aug;124(8):3352-63
pubmed: 24983321
Viruses. 2018 Nov 21;10(11):
pubmed: 30469363
Nat Commun. 2014 Nov 05;5:5377
pubmed: 25369785
Hepatology. 2003 May;37(5):1189-98
pubmed: 12717401
Gastroenterology. 2015 Jul;149(1):190-200.e2
pubmed: 25754160
Gastroenterology. 2012 Jul;143(1):223-233.e9
pubmed: 22503792
Gastroenterology. 2011 Oct;141(4):1422-31, 1431.e1-6
pubmed: 21763239
Lancet Infect Dis. 2012 Jan;12(1):36-44
pubmed: 22032844
J Exp Med. 2012 Jan 16;209(1):61-75
pubmed: 22213804
Gastroenterology. 2019 Jan;156(2):418-430
pubmed: 30268785
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Hepatol. 2015 Apr;62(1 Suppl):S87-99
pubmed: 25920094
Gastroenterology. 2016 Mar;150(3):696-706.e3
pubmed: 26584604
Hepatol Commun. 2017 Sep;1(7):586-594
pubmed: 29202115
PLoS One. 2007 Jul 25;2(7):e649
pubmed: 17653276
J Immunol. 2013 Nov 15;191(10):5026-35
pubmed: 24101548
Cell Rep. 2016 Jun 14;15(11):2331-9
pubmed: 27264178
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Gastroenterology. 1999 Oct;117(4):933-41
pubmed: 10500077
Science. 1998 Oct 2;282(5386):103-7
pubmed: 9756471
J Clin Invest. 1996 Aug 1;98(3):706-14
pubmed: 8698862
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Gastroenterology. 2019 Jan;156(2):369-383
pubmed: 30267712